NEW YORK (GenomeWeb News) – Genomind today announced a partnership with Emory University to commercialize a blood-based screening test for mild cognitive impairment and Alzheimer's disease.

Under the terms of the deal, Genomind has attained the exclusive rights to commercialize blood-based protein biomarkers for assessment of the conditions. Other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.